GlassScriptPhysician profile
James S Price
NPI 1457344822
$636.66
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $155 · 2021: $224 · 2022: $39.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $212.51 | 2019-2022 | |
| Pfizer INC. | $129.33 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.95 | 2019-2022 | |
| Tris Pharma INC | $46.40 | 2019 | |
| Seqirus USA INC | $36.97 | 2021 | |
| Cranial Technologies, INC | $36.36 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $23.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.26 | 2019 | |
| Sobi, INC | $16.89 | 2019 | |
| Sanofi Pasteur INC. | $15.24 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.50 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.